FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Jin David</u>				2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]										Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner					
I					3. Date of Earliest Transaction (Month/Day/Year) 02/10/2023									X	Officer (g below)				pecify
1111 KANE CONCOURSE SUITE 301					4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
(Street) BAY HARBOR FL 33154													X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zi <sub>l</sub>	o)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				. Transaction late Execution Date, if any (Month/Day/Year)		Execution Date, if any		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			) or 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
						Code	v	Amount (A) or (D)		Price	(Instr. 4)								
COMMON STOCK, PAR VALUE \$0.001 02/2				02/1	/10/2023				P		35,928		A	\$0.835	1,438,757(1)			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	z. Conversion Or Exercise Price of Derivative Security  3. Transaction Date Execution Date, if any (Month/Day/Year)		ate, T	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				e Sec Deri (Insi		7. Title and Amou Securities Underly Derivative Securit (Instr. 3 and 4)  Amor Nun Title		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	e C S F Illy C	10. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

1. The total holdings include 1,350,000 shares underlying deferred restricted stock units.

/s/ David Jin

02/14/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.